Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD
Sponsored by University of Michigan
About this trial
Last updated 4 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Ended 6 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- neonates and infants who are at least 28 weeks corrected gestational age at the time of enrollment who are parenteral nutrition (PN) naive
- current direct bilirubin <2 mg/dL
- any of the following conditions:
- meconium ileus and peritonitis
- gastroschisis
- omphalocele >4cm or with liver herniated outside of the abdominal cavity
- necrotizing enterocolitis requiring surgical intervention
- volvulus
- intestinal atresia with >50% bowel loss
Exclusion Criteria
- weight <1 kg
- metabolic pathway defect which is associated with liver dysfunction in the neonatal period, including: hereditary fructose intolerance, galactosemia due to transferase deficiency and neonatal tyrosinemia, and/or disorder of lipid metabolism
- hepatic insufficiency as documented by either a biopsy with cirrhosis and/or marked aberration in synthetic function
- renal failure
- primary or secondary liver disease, regardless of liver function (includes hepatitis)
- use of extracorporeal membrane oxygenation (ECMO)
- suspected congenital obstruction of the hepatobiliary tree
- documented active infection which may be communicable, including infections hepatitis or HIV
- previous receipt of choleretic agents
- currently receiving phenobarbital or other barbiturates
- history of PNAC
- direct bilirubin >=2 mg/dL at time of enrollment
- congenital or acquired anomaly which will require major cardiovascular surgery
- major congenital or chromosomal anomaly
- hypoxic ischemic encephalopathy
- congenital defect of the brain
- major seizure disorder